For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

GHRP-2 (pralmorelin): origin, structure and research history

Research Library › GHRH & Ghrelin-Receptor

GHRP-2 (growth hormone-releasing peptide-2), also known by the nonproprietary name pralmorelin, is a synthetic hexapeptide designed to act at the growth hormone secretagogue (ghrelin) receptor. It belongs to the GHRP family that originated in Cyril Bowers’ laboratory at Tulane University in the 1980s. As of 22 Oct 2026 it is approved in Japan only as a diagnostic agent, is not FDA-approved, and is on FDA’s Category 2 list for compounding.

Key facts

TypeSynthetic 6-amino-acid peptide (hexapeptide)
Derived fromThe GHRP family, a successor to GHRP-6
First describedGHRP family founded 1984 at Tulane University; GHRP-2 followed
Developed byCyril Y. Bowers' program, Tulane University; marketed in Japan by Kaken Pharmaceutical
Designed targetGrowth hormone secretagogue (ghrelin) receptor on the pituitary
Regulatory status (Oct 2026)Approved in Japan as a diagnostic (pralmorelin); not FDA-approved; FDA Category 2 since 2023; named on WADA 2026 list (S2)

Who developed it

GHRP-2 grew out of the growth hormone-releasing peptide program led by Cyril Y. Bowers at Tulane University Medical School in New Orleans. After his team, including Frank Momany, reported GHRP-6 in 1984, further six-amino-acid relatives followed, among them GHRP-2 and hexarelin [1][2].

In Japan, GHRP-2 was developed as pralmorelin hydrochloride and marketed by Kaken Pharmaceutical under the product name GHRP [3].

What it was designed to target

The GHRP family began with synthetic analogs of enkephalin, a natural opioid peptide, which Bowers found could prompt pituitary cells to release growth hormone [2]. Like GHRP-6, GHRP-2 is a short synthetic chain that includes D-amino acids and has no counterpart in nature; Bowers described the class as being “of unnatural origin” [1][2].

GHRP-2 is designed to bind the growth hormone secretagogue receptor (GHS-R) on the pituitary. The receptor’s natural ligand was unknown until 1999, when Masayasu Kojima, Kenji Kangawa and colleagues identified ghrelin, a hormone made in the stomach [4].

Why it was created

The GHRPs acted through a route separate from GHRH. Bowers viewed them as tools for investigating and testing growth hormone regulation, and as pointers to an undiscovered natural hormone [1]. In a 1998 review he wrote that GHRP mirrors “a new natural hypothalamic hormone yet to be isolated.” Ghrelin, reported the next year from the stomach rather than the hypothalamus, filled that gap [1][4]. That diagnostic direction is the one GHRP-2 ultimately took in Japan, where pralmorelin was approved as a diagnostic agent [3].

Research timeline

  • 1984: Bowers’ team reports GHRP-6, founding the GHRP family [2].
  • 1998: Bowers writes that GHRPs mirror an unidentified natural hypothalamic hormone [1].
  • 1999: Ghrelin is identified as the natural ligand of the GHRP receptor [4].
  • Japan: Pralmorelin hydrochloride (Kaken) is listed among new drug approvals as a diagnostic [3].
  • 2023: FDA places GHRP-2 in Category 2 for compounding [5].

Regulatory status as of October 2026

As of 22 Oct 2026, GHRP-2 is approved in Japan, as pralmorelin, solely as a diagnostic agent [3]. It is not FDA-approved. In 2023 FDA placed GHRP-2 in Category 2 for outsourcing facilities, citing reports of serious adverse events and effects on cortisol and blood glucose [5]. It was not among the 12 peptides FDA removed from Category 2 in April 2026 [6], nor among the seven peptides its advisory committee voted on in July 2026 [7].

GHRP-2 is covered by the 2026 World Anti-Doping Agency Prohibited List under S2 as a growth hormone-releasing peptide, prohibited at all times [8].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

What is pralmorelin?

Pralmorelin is the nonproprietary drug name for GHRP-2. As pralmorelin hydrochloride, it is approved in Japan as a diagnostic agent marketed by Kaken Pharmaceutical.

Who developed GHRP-2?

GHRP-2 came from Cyril Bowers’ growth hormone-releasing peptide program at Tulane University, which first reported GHRP-6 in 1984.

Is GHRP-2 FDA approved?

No. As of 22 Oct 2026 GHRP-2 is not FDA-approved, and FDA has listed it in Category 2 for compounding since 2023.

What is the difference between GHRP-2 and GHRP-6?

Both are six-amino-acid peptides from the same Tulane program that target the growth hormone secretagogue receptor. GHRP-6 came first, in 1984; GHRP-2 is a later relative and the only one of the two approved anywhere, as a diagnostic in Japan.

Sources

  1. Bowers CY (Tulane University Medical School, New Orleans). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316–1329. doi:10.1007/s000180050257. Link
  2. Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. doi:10.1177/1179546817694558. Link
  3. KEGG DRUG. D02040 Pralmorelin hydrochloride (JAN); product GHRP (Kaken Pharmaceutical), Japan; efficacy: diagnostic; listed under new drug approvals in Japan. Link
  4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402:656–660. doi:10.1038/45230. Link
  5. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
  6. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  7. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  8. World Anti-Doping Agency. 2026 Prohibited List, S2.2.4 (GHRH and its analogues; growth hormone secretagogues; GH-releasing peptides). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top